Changes in breast cancer management during the Corona Virus Disease 19 pandemic: An international survey of the European Breast Cancer Research Association of Surgical Trialists (EUBREAST)

Autor: Oreste Gentilini, Orit Kaidar-Person, Maria Luisa Gasparri, Philip Poortmans, T. Kuehn, Diana Lueftner
Rok vydání: 2020
Předmět:
Coping (psychology)
medicine.medical_treatment
Virus diseases
Breast surgery
Systemic therapy
Antineoplastic Agents
Immunological
COVID-19 Testing
Breast cancer
0302 clinical medicine
Surveys and Questionnaires
Pandemic
Mass Screening
030212 general & internal medicine
skin and connective tissue diseases
Mastectomy
Disease Management
General Medicine
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Europe
Radiation therapy
Chemotherapy
Adjuvant
030220 oncology & carcinogenesis
Coronavirus Infections
medicine.medical_specialty
COVID-19 Vaccines
Antineoplastic Agents
Hormonal
Pneumonia
Viral
Antineoplastic Agents
Breast Neoplasms
Workload
lcsh:RC254-282
Article
Time-to-Treatment
Betacoronavirus
03 medical and health sciences
medicine
Humans
Chemotherapy
Pandemics
Radiotherapy
Clinical Laboratory Techniques
SARS-CoV-2
business.industry
Gene Expression Profiling
COVID-19
medicine.disease
Triage
Emergency medicine
Radiotherapy
Adjuvant
Surgery
Human medicine
business
Delivery of Health Care
Zdroj: The Breast
Breast (Edinburgh, Scotland)
Breast, Vol 52, Iss, Pp 110-115 (2020)
ISSN: 0960-9776
Popis: Background Corona Virus Disease 19 (COVID-19) had a worldwide negative impact on healthcare systems, which were not used to coping with such pandemic. Adaptation strategies prioritizing COVID-19 patients included triage of patients and reduction or re-allocation of other services. The aim of our survey was to provide a real time international snapshot of modifications of breast cancer management during the COVID-19 pandemic. Methods A survey was developed by a multidisciplinary group on behalf of European Breast Cancer Research Association of Surgical Trialists and distributed via breast cancer societies. One reply per breast unit was requested. Results In ten days, 377 breast centres from 41 countries completed the questionnaire. RT-PCR testing for SARS-CoV-2 prior to treatment was reported by 44.8% of the institutions. The estimated time interval between diagnosis and treatment initiation increased for about 20% of institutions. Indications for primary systemic therapy were modified in 56% (211/377), with upfront surgery increasing from 39.8% to 50.7% (p
Highlights • Management of breast cancer patients was modified during the pandemic. • Waiting time increased during the pandemic in 20% of the institutions. • A workload reduction of ≥50% was reported in 1/3 and relocation of the centres in 13%. • It is unknown whether these changes will affect outcome of breast cancer patients.
Databáze: OpenAIRE
Externí odkaz: